• Mashup Score: 4
    High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538 - 1 year(s) ago

    PURPOSE Although level 1 evidence supports 45-Gy twice-daily radiotherapy as standard for limited-stage small-cell lung cancer, most patients receive higher-dose once-daily regimens in clinical practice. Whether increasing radiotherapy dose improves outcomes remains to be prospectively demonstrated. METHODS This phase III trial, CALGB 30610/RTOG 0538 (ClinicalTrials.gov identifier: NCT00632853),…

    Source: Journal of Clinical Oncology
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HenningWillers
      HenningWillers

      1/ Great to see CALGB 30610/RTOG 0538 finally out! 🚨70 Gy/7 wk equivalent to 45 Gy BID/3 wk🚨 Some thoughts 1⃣Interesting that increased G3+ lymphopenia in 70Gy does not result in worse outcomes?! @StevenLin_MDPhD @CGrassberger @OncoAlert #LCSM https://t.co/su7WjYRuU9

  • Mashup Score: 1
    Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium - 1 year(s) ago

    PURPOSE Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen–directed chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple myeloma (RRMM) on the basis of the phase II pivotal KarMMa trial, which demonstrated best overall and ≥ complete response rates of 73% and 33%, respectively. We report clinical outcomes with standard-of-care (SOC) ide-cel…

    Source: Journal of Clinical Oncology
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Transplant_Doc
      Transplant_Doc

      Ide-cel for RRMM: Real-World Experience From the Myeloma CAR-T Consortium. 196 leukapheresed, 159 (81%) received ide-cel. ORR: 84%, CR: 42%. Median PFS: 8.5 months, median OS: 12.5 months. CRS/NT: 82%/18% #mmsm #bmtsm @SurbhiSidanaMD @DrKrinaPatel https://t.co/LSgiV0jML6

  • Mashup Score: 3
    Flashback Foreword: Adjuvant Interferon α-2b for High-Risk Melanoma - 1 year(s) ago

    Flashback Foreword: Adjuvant Interferon α-2b for High-Risk MelanomaThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For…

    Source: Journal of Clinical Oncology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JCO_ASCO
      JCO_ASCO

      🎊 Celebrating #JCO's 40th: Read Dr. Schwartz's Flashback Foreword to the top-cited #JCO article Adjuvant Interferon a-2b for High-Risk Melanoma (1996) ➡️ https://t.co/kuKF4NbzLj https://t.co/EojhbPiycz

  • Mashup Score: 1
    Multiomic characterization to reveal a distinct molecular landscape in young-onset pancreatic cancer. - 1 year(s) ago

    594 Background: Young-onset pancreatic cancer (YOPC; < 50 years at diagnosis) has been associated with male preponderance, extensive smoking history, and a trend towards improved survival compared with average-onset pancreatic cancer (AOPC; ≥70 years). However, the genomic and transcriptomic correlates underlying these clinical differences are incompletely understood. Using a large matched...

    Source: Journal of Clinical Oncology
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DrJashDatta
      DrJashDatta

      💪🏽! Yes, several molecular differences in YOPC. ✅out sneak peek of study from our group examining this❓using @carisls dataset. @IOgobuiro won #HarveyBaker @SocSurgOnc #SSO2022 for this. Manuscript coming soon!! #pancsm @NbmerchantMD @SyedAAhmad5 et al👉🏼https://t.co/UHDfohvaLi https://t.co/oenmmdBmAc

  • Mashup Score: 1
    Low-Grade Prostate Cancer: Time to Stop Calling It Cancer - 1 year(s) ago

    Section:IntroductionProstate-specific antigen (PSA) screening for prostate cancer (PCa) remains highly controversial, largely because it is unclear whether the primary benefits of reducing rates of metastases and cancer mortality are worth the risks of overdiagnosis, overtreatment, and potential treatment-related morbidity. A major contributing factor to overdiagnosis and overtreatment is the…

    Source: Journal of Clinical Oncology
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of chadinabhan
      chadinabhan

      Gleason 6 Prostate Cancer; should it be called cancer? @uroegg & Dr. Epstein debated the topic in the pages of @JCO_ASCO https://t.co/hsUteqqNrX And https://t.co/to3HCJE1Tb They visit #HealthcareUnfiltered to continue the debate. A must B4 #GU23 @ASCO https://t.co/iIxvdI710S https://t.co/aZSLMcel8b

  • Mashup Score: 1
    Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography - 1 year(s) ago

    PURPOSE Low-dose computed tomography (LDCT) for lung cancer screening is effective, although most eligible people are not being screened. Tools that provide personalized future cancer risk assessment could focus approaches toward those most likely to benefit. We hypothesized that a deep learning model assessing the entire volumetric LDCT data could be built to predict individual risk without…

    Source: Journal of Clinical Oncology
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of StephenVLiu
      StephenVLiu

      Report on deep learning model (Sybil) @JCO_ASCO. With one low dose CT and no clinical data or annotations, predicts lung cancer risk. Concordance index for NLST over 6y was 0.75. Early days but is this the future of personalized cancer screening? https://t.co/0Ns0XCo0XB

Load More